APLS
Price
$19.28
Change
-$0.19 (-0.98%)
Updated
Jul 21, 04:59 PM (EDT)
Capitalization
2.45B
21 days until earnings call
DYAI
Price
$1.00
Change
+$0.03 (+3.09%)
Updated
Jul 21, 04:50 PM (EDT)
Capitalization
29.3M
16 days until earnings call
Interact to see
Advertisement

APLS vs DYAI

Header iconAPLS vs DYAI Comparison
Open Charts APLS vs DYAIBanner chart's image
Apellis Pharmaceuticals
Price$19.28
Change-$0.19 (-0.98%)
Volume$13.03K
Capitalization2.45B
Dyadic International
Price$1.00
Change+$0.03 (+3.09%)
Volume$200
Capitalization29.3M
APLS vs DYAI Comparison Chart in %
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. DYAI commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and DYAI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (APLS: $19.47 vs. DYAI: $0.97)
Brand notoriety: APLS and DYAI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 86% vs. DYAI: 62%
Market capitalization -- APLS: $2.45B vs. DYAI: $29.3M
APLS [@Biotechnology] is valued at $2.45B. DYAI’s [@Biotechnology] market capitalization is $29.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whileDYAI’s FA Score has 0 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • DYAI’s FA Score: 0 green, 5 red.
According to our system of comparison, APLS is a better buy in the long-term than DYAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 6 TA indicator(s) are bullish while DYAI’s TA Score has 3 bullish TA indicator(s).

  • APLS’s TA Score: 6 bullish, 3 bearish.
  • DYAI’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, APLS is a better buy in the short-term than DYAI.

Price Growth

APLS (@Biotechnology) experienced а +0.15% price change this week, while DYAI (@Biotechnology) price change was -1.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.21%. For the same industry, the average monthly price growth was +15.57%, and the average quarterly price growth was +33.92%.

Reported Earning Dates

APLS is expected to report earnings on Aug 11, 2025.

DYAI is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+2.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($2.45B) has a higher market cap than DYAI($29.3M). APLS YTD gains are higher at: -38.985 vs. DYAI (-44.354). DYAI has higher annual earnings (EBITDA): -5.32M vs. APLS (-176.08M). APLS has more cash in the bank: 358M vs. DYAI (7.35M). DYAI has less debt than APLS: DYAI (5.07M) vs APLS (470M). APLS has higher revenues than DYAI: APLS (776M) vs DYAI (3.34M).
APLSDYAIAPLS / DYAI
Capitalization2.45B29.3M8,352%
EBITDA-176.08M-5.32M3,311%
Gain YTD-38.985-44.35488%
P/E RatioN/AN/A-
Revenue776M3.34M23,206%
Total Cash358M7.35M4,871%
Total Debt470M5.07M9,279%
FUNDAMENTALS RATINGS
APLS vs DYAI: Fundamental Ratings
APLS
DYAI
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9899
PRICE GROWTH RATING
1..100
6286
P/E GROWTH RATING
1..100
10070
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APLS's Valuation (70) in the Medical Distributors industry is in the same range as DYAI (94) in the Biotechnology industry. This means that APLS’s stock grew similarly to DYAI’s over the last 12 months.

APLS's Profit vs Risk Rating (100) in the Medical Distributors industry is in the same range as DYAI (100) in the Biotechnology industry. This means that APLS’s stock grew similarly to DYAI’s over the last 12 months.

APLS's SMR Rating (98) in the Medical Distributors industry is in the same range as DYAI (99) in the Biotechnology industry. This means that APLS’s stock grew similarly to DYAI’s over the last 12 months.

APLS's Price Growth Rating (62) in the Medical Distributors industry is in the same range as DYAI (86) in the Biotechnology industry. This means that APLS’s stock grew similarly to DYAI’s over the last 12 months.

DYAI's P/E Growth Rating (70) in the Biotechnology industry is in the same range as APLS (100) in the Medical Distributors industry. This means that DYAI’s stock grew similarly to APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSDYAI
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
74%
Bullish Trend 4 days ago
87%
Momentum
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
78%
MACD
ODDS (%)
Bullish Trend 4 days ago
87%
N/A
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
76%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 12 days ago
80%
Declines
ODDS (%)
Bearish Trend 22 days ago
79%
Bearish Trend 8 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
79%
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GKIRX26.770.02
+0.07%
Goldman Sachs Income Builder Inv
KMKCX74.65-0.02
-0.03%
Kinetics Market Opportunities Adv C
FIFRX146.16-0.10
-0.07%
Franklin Growth R6
GSSIX40.78-0.18
-0.44%
Goldman Sachs Small Cap Value Inst
CAMZX17.46-0.12
-0.68%
Cambiar Small Cap Instl

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with ROIV. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
-2.84%
ROIV - APLS
48%
Loosely correlated
-1.80%
ARWR - APLS
46%
Loosely correlated
-11.09%
IMVT - APLS
45%
Loosely correlated
-2.02%
DNLI - APLS
44%
Loosely correlated
-3.65%
KYMR - APLS
44%
Loosely correlated
-0.37%
More

DYAI and

Correlation & Price change

A.I.dvisor tells us that DYAI and CGTX have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DYAI and CGTX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYAI
1D Price
Change %
DYAI100%
-0.63%
CGTX - DYAI
27%
Poorly correlated
-3.82%
QSI - DYAI
25%
Poorly correlated
-3.30%
VYNE - DYAI
24%
Poorly correlated
-3.33%
NAUT - DYAI
23%
Poorly correlated
-1.33%
APLS - DYAI
23%
Poorly correlated
-2.84%
More